{"schema":"hottub-news/story/v1","story":"st_35yz6h3mct434bhrowvq","title":"Chugai Set to Reclaim Myostatin Drug Rights From Roche After Obesity Trial Falls Short","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/chugai-set-to-reclaim-myostatin-drug-rights-from-roche-after-obesity-35yz6h3mct","count":1,"items":[{"id":"n_35yz6h3mct434bhrowvq","seq":429363,"kind":"article","title":"Chugai Set to Reclaim Myostatin Drug Rights From Roche After Obesity Trial Falls Short","url":"https://tokyobrief.com/articles/chugai-emugrobart-gym329-obesity-halt-sma-restart","summary":"An interim analysis of Chugai's Phase 2 obesity trial for the myostatin antibody emugrobart found the targeted weight loss unlikely, so Roche is exiting the program entirely and is set to return all license rights to Chugai, which is now preparing, but has not decided, a possible return to spinal muscular atrophy development.","published":"2026-09-28T11:54:23Z","seen":"2026-09-28T12:52:19Z","lang":"ja","country":"JP","source":{"id":"kite-tokyobrief-com-a5667e","name":"tokyobrief.com","domain":"tokyobrief.com","outlet":{"wikidata":"Q141513445","name":"Tokyo Brief","type":"other","designations":["newsletter"]}},"via":"kite-tokyobrief-com-a5667e","entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://tokyobrief.com/media/tokyo-brief-2026-09-28-chugai-emugrobart-gym329-obesity-halt-sma-restart-e520d5eacae3b80ec46976d6ad6c4db0159620333a3da335a3834d1ebed1b652.png?v=card","story":"st_35yz6h3mct434bhrowvq","category":"economy-business","category_p":0.47999998927116394,"category2":"health","sentiment":"neutral","tone":-0.17000000178813934,"political":0.23999999463558197}]}